Lin Liu1,2, Dan Li1, Zhengqi Chen3, Jian Yang4, Yushui Ma1, Haidong Cai1, Chengxiang Shan5, Zhongwei Lv1, Xiaoping Zhang1,2. 1. Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. 2. Department of Institution of Interventional and Vascular Surgery, Tongji University, Shanghai, China. 3. Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. 4. Department of Nuclear Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China. 5. Department of General Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Abstract
AIMS: Anaplastic thyroid cancer(ATC) is one of the most aggressive solid tumors. Mutations in the p53 gene are common in anaplastic thyroid cancer, but the effects of p53 mutations are yet to be elucidated. Here, we investigated the role of p53 in ATC. METHODS: p53 mutation was detect by immunohistochemistry in ATC tissues. Expression of NIS were measured using immunohistochemistry, qRT-PCR, western blot, immunofluorescence in ATC tissues and cell line 8505c. Luciferase reporter assay was performed to examine the effect of wild-type p53 on NIS. Radioiodide uptake assay and flow cytometry analysis were used to detect the role of wild-type p53 on radioiodide uptake.and cell apoptosis in ATC cell line. RESULTS: We showed that the p53 mutation can be detected in ATC tissues. Furthermore, we demonstrated that wild-type p53 transactivated the NIS promoter. In 8505c cells transfected with wild-type p53, treatment with radioiodine resulted in increased radioiodine uptake and increased apoptotic cell death compared with 8505c cells harboring the p53 mutation. CONCLUSION: In summary, transfection with wild-type p53 can increase the therapeutic effect of radioiodine by regulating the expression of the NIS.
AIMS: Anaplastic thyroid cancer(ATC) is one of the most aggressive solid tumors. Mutations in the p53 gene are common in anaplastic thyroid cancer, but the effects of p53 mutations are yet to be elucidated. Here, we investigated the role of p53 in ATC. METHODS:p53 mutation was detect by immunohistochemistry in ATC tissues. Expression of NIS were measured using immunohistochemistry, qRT-PCR, western blot, immunofluorescence in ATC tissues and cell line 8505c. Luciferase reporter assay was performed to examine the effect of wild-type p53 on NIS. Radioiodide uptake assay and flow cytometry analysis were used to detect the role of wild-type p53 on radioiodide uptake.and cell apoptosis in ATC cell line. RESULTS: We showed that the p53 mutation can be detected in ATC tissues. Furthermore, we demonstrated that wild-type p53 transactivated the NIS promoter. In 8505c cells transfected with wild-type p53, treatment with radioiodine resulted in increased radioiodine uptake and increased apoptotic cell death compared with 8505c cells harboring the p53 mutation. CONCLUSION: In summary, transfection with wild-type p53 can increase the therapeutic effect of radioiodine by regulating the expression of the NIS.
Authors: Ana Filipa Brito; Ana Margarida Abrantes; Ricardo Teixo; Ana Salomé Pires; Ana Cláudia Ribeiro; Rafael Fernandes Ferreira; Alexandra Fernandes; Tiago Puga; Mafalda Laranjo; Francisco Caramelo; Ilka Boin; Douglas M Jefferson; Ana Cristina Gonçalves; Ricardo Martins; Joana Rodrigues; Ilda Patrícia Ribeiro; Joana Barbosa De Melo; Ana Bela Sarmento-Ribeiro; Isabel Marques Carreira; Doroteia Souza; José Guilherme Tralhão; Maria Filomena Botelho Journal: Int J Oncol Date: 2020-01-10 Impact factor: 5.650
Authors: M Rashid; Amit Agarwal; Roma Pradhan; Nelson George; Niraj Kumari; M Sabaretnam; Gyan Chand; Anjali Mishra; Gaurav Agarwal; Saroj Kanta Mishra Journal: Indian J Endocrinol Metab Date: 2019 Jul-Aug